Regeneron gains cemdisiran review milestones, shares trade around 611 dollars on Nasdaq
22.06.2026 - 19:07:31 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-22, 19:06.
Regeneron (US75886F1075) reported a regulatory step forward for its neuromuscular pipeline on Monday. The Nasdaq-listed biotech said the FDA and the European Medicines Agency have accepted regulatory submissions for cemdisiran in generalized myasthenia gravis, according to a June 22 GlobeNewswire release.GlobeNewswire announcement on cemdisiran submissions
What the cemdisiran update says
The June 22 communication states that both the U.S. Food and Drug Administration and the EMA’s Committee for Medicinal Products for Human Use have formally validated cemdisiran filings for adult patients with generalized myasthenia gravis.GlobeNewswire announcement on cemdisiran submissions The company highlights that cemdisiran targets complement component C5, an established pathway in gMG therapies.
Regeneron adds that the submissions draw on data from a pivotal phase 3 study in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, although detailed efficacy metrics are not reiterated in the brief release.GlobeNewswire announcement on cemdisiran submissions Cemdisiran is positioned alongside rivals such as AstraZeneca’s Alexion unit, which already markets complement inhibitors for gMG.
Analyst views and Nasdaq trading levels
On Nasdaq, Regeneron shares recently changed hands around 606 to 611 dollars intraday on June 22, with Robinhood quoting 606.26 dollars and market cap of roughly 63.6 billion dollars at one snapshot.Robinhood quote for REGN MarketBeat lists the stock at about 601 dollars earlier in the session, indicating moderate day-to-day volatility in a tight range.MarketBeat overview for Regeneron
From a rating perspective, recent analyst actions show a cautious tilt at elevated valuations. Finviz data point to downgrades on May 18, 2026, when Leerink Partners moved Regeneron from Outperform to Market Perform with a 641 dollar target and Citigroup shifted from Buy to Neutral with a 700 dollar target, while earlier this year Barclays and BofA Securities took more constructive stances with targets above 860 dollars.Finviz analyst table for REGN
All news and data on the Regeneron shares
Key figures on REGN, from Nasdaq trading and analyst targets to pipeline milestones such as cemdisiran, can be compared over time for a clearer view of the stock.
How Regeneron earns its money
Regeneron generates most of its revenue from flagship ophthalmology drug Eylea, sold for retinal diseases, and from the Dupixent franchise for atopic dermatitis and asthma, co-commercialized with Sanofi.FinancialData profile of Regeneron The company complements these franchises with an expanding pipeline in immunology and oncology, where candidates like cemdisiran are expected to broaden the portfolio.
Where the shares trade today
The Regeneron shares (US75886F1075) trade on Nasdaq under the ticker REGN and were quoted around 611.07 dollars in intraday trading on June 22, 2026, according to eToro, with the company valued at over 60 billion dollars.eToro quote and analyst overview for REGN
Key data on the Regeneron shares
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- WKN: 881535
- Ticker: REGN
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 17:20): 611.07 USD
- Market cap: 63.6 billion USD (as of 2026-06-22)
- Sector / industry: Biotechnology / Biopharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Historical performance is not a reliable indicator of future results, and readers should consider their own financial situation and consult a professional advisor before making investment decisions.
